Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: January 6, 2009
Last updated: March 4, 2013
Last verified: March 2013
This study will evaluate pharmacokinetics and safety of intravenous micafungin in neonates with suspected candida infection

Condition Intervention Phase
Drug: Micafungin
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Assessment of micafungin plasma pharmacokinetic parameters [ Time Frame: Day 4 ]

Secondary Outcome Measures:
  • Monitor adverse events [ Time Frame: 11 or 12 Days ]

Enrollment: 13
Study Start Date: August 2007
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1. micafungin lower dose Drug: Micafungin
IV Administration
Other Names:
  • Mycamine
  • FK463
Experimental: 2. micafungin higher dose Drug: Micafungin
IV Administration
Other Names:
  • Mycamine
  • FK463

Detailed Description:
Subjects will be stratified by weight to receive one of two doses of study drug

Ages Eligible for Study:   up to 120 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent and HIPAA authorization of the infant's parent or legally authorized representative must be obtained prior to study entry
  • Infant has sufficient venous access to permit study drug dosing
  • Infant is suspected to have a systemic Candida infection and appropriate cultures (blood with or without urine/CSF) are obtained at the time of study entry

Exclusion Criteria:

  • Infant has a history of anaphylaxis, hypersensitivity, or any serious reaction to the echinocandin class of antifungals
  • Infant has received an echinocandin within one month prior to study entry
  • Infant has a concomitant medical condition which, in the opinion of the investigator and/or medical advisor, may create an unacceptable additional risk
  • Infant has a life expectancy of less than 96 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00818584

United States, Alabama
Birmingham, Alabama, United States, 35233
United States, California
Orange, California, United States, 92868
United States, Kentucky
Louisville, Kentucky, United States, 40202
United States, Missouri
Kansas City, Missouri, United States, 64108
United States, North Carolina
Durham, North Carolina, United States, 27710
United States, Texas
Dallas, Texas, United States, 75390
United States, Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Use Central Contact Astellas Pharma US, Inc.
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT00818584     History of Changes
Obsolete Identifiers: NCT00906230
Other Study ID Numbers: 9463-CL-2104
Study First Received: January 6, 2009
Last Updated: March 4, 2013

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Antifungal Agents
Anti-Infective Agents processed this record on April 28, 2017